Evoq Remedies Ltd (EVOQ) — shareholding pattern, promoter holding, financials and share price
About Evoq Remedies Ltd (EVOQ)
Evoq Remedies Ltd operates in the Trading & Distributors industry, within the Services sector. It trades on the NSE as EVOQ and on the BSE under scrip code 543500. Its ISIN is INE0JVD01011.
Incorporated in 2010, EVOQ Remedies Ltd is in the pharmaceutical business. [1]
Evoq Remedies Limited is engaged in the marketing, trading, and distribution of pharmaceutical formulation products, serving a wide range of healthcare needs from antibiotic drugs to multivitamins.
The company began its operations in 2018, despite being incorporated in 2010, and has since established itself as a significant player in the pharmaceutical raw materials market.
Listed peers in Trading & Distributors: Yarn Syndicate Ltd, Aravali Securities & Finance Ltd, Ambitious Plastomac Company Ltd, Siddheswari Garments Ltd, Saianand Commercial Ltd, Nouveau Global Ventures Ltd.
Valuation & Returns
10 Jul 2026At ₹2.2 a share on 10 Jul 2026, Evoq Remedies Ltd (EVOQ) was valued at a price-to-book of 0.12x on a book value of ₹17.79 per share. Solomo computes return on equity of -0.54% and return on capital employed of -0.57% from filed results.
- Industry P/E
- 21.24x
- P/B
- 0.12x
- Book value / share
- ₹17.79
- ROE
- -0.54%
- ROCE
- -0.57%
- ROA
- -0.46%
- Debt / equity
- 0x
- Dividend yield
- 0%
- EBITDA margin
- -0.78%
- 52-week range
- ₹2.14 – ₹6.11
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Evoq Remedies Ltd (EVOQ) reported revenue of ₹25.51 crore, net profit of ₹-0.24 crore and earnings per share of ₹-0.1. That compares with revenue of ₹11.76 crore and net profit of ₹0.09 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, net profit ₹-0.29 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 16.78 | 20.39 | 4.05 | 11.76 | 25.51 |
| Net profit (₹ cr) | 1.09 | 1.62 | 0.45 | 0.09 | -0.24 |
| EPS (₹) | 0.8 | 1.19 | 0.33 | 0.04 | -0.1 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | 5.32% | -11.19% | 190.37% |
| Profit growth | 211.65% | -56.76% | -80.00% |
Ownership Summary
Mar 2026As of Mar 2026, promoters hold 0.02% of Evoq Remedies Ltd (EVOQ). Market capitalisation was ₹5 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2022.
Largest disclosed public shareholders in Mar 2026: DHRUV GANJI 11.35%, PRASHANT SEVANTIKAR 11.35%, SURYA PRAKASH JETHLIA 2.62%, NILESH M SUHAGIYA 2.09%, HUF 1.59%, ANAND MOHAN 1.53%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Mar 2026 | 0.02% | - | - | - | 99.98% |
| Sep 2025 | 11.21% | - | - | - | 88.79% |
| Mar 2025 | 11.21% | - | - | - | 88.79% |
| Sep 2024 | 11.21% | - | - | - | 88.79% |
| Mar 2024 | 20.53% | - | - | - | 79.47% |
| Sep 2023 | 73.53% | - | - | - | 26.47% |
| Mar 2023 | 73.53% | - | - | - | 26.47% |
| Sep 2022 | 73.53% | - | - | - | 26.47% |